AT2 receptor agonist C21

SKU: orb1707632

Description

Buloxibutid (C21) is a selective AT2 receptor agonist with high affinity (Ki = 0.4 nM) and significant selectivity over the AT1 receptor. It is a valuable research tool for investigating the renin-angiotensin system in models of cardiovascular and renal disease, fibrosis, and inflammation, both in vitro and in vivo.

Research Area

Epigenetics & Chromatin; Pharmacology & Drug Discovery

Key Properties

• CAS Number: 477775-14-7
• MW: 475.62
• Purity: 98.58% (May vary between batches)
• Formula: C₂₃H₂₉N₃O₄S₂
• SMILES: CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccnc2)cc1
• Target: RAAS
• Solubility: DMSO:22.5 mg/mL (47.31 mM);10% DMSO+40% PEG300+5% Tween-80+45% Saline:2 mg/mL (4.21 mM)

Bioactivity

• Target IC50:
  AT1:>10 μM(ki)|AT2:0.4 nM(ki)
• In Vivo:
  Buloxibutid, with an oral bioavailability of 20-30% and a 4-hour half-life in rats, induces neurite cell outgrowth, stimulates p42/p44mapk, enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers mean arterial blood pressure in anesthetized, spontaneously hypertensive rats.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AT2 receptor agonist C21, AT2, AT2 receptor, AT1, Buloxibutid

Compound Identifiers

PubChem CID

9804984